Valion Bio, Inc. has announced that it received a notice of effectiveness for its recent filing on October 20, 2026. This development is crucial for the company as it signifies compliance with regulatory requirements, allowing Valion to move forward with its business objectives.
Valion Bio, Inc. operates in the pharmaceutical preparations sector, as indicated by its Standard Industrial Classification (SIC) code of 2834. The company is listed on the Nasdaq under the ticker symbol VBIO. Valion is categorized as an emerging growth company, which highlights its status as a developing player in the pharmaceutical industry.
The filing states, "Accepted 2026-10-21 00:15:02" and confirms the effectiveness date of October 20, 2026. Details were not available in the SEC filing regarding the specific implications of this notice.
This announcement may affect various stakeholders, including investors, partners, and competitors in the pharmaceutical preparations industry. As Valion progresses, it may influence market dynamics and competitive strategies within the sector.
The filing does not say what happens next, leaving the future steps for Valion Bio open-ended.
Company Information
Valion Bio, Inc. is incorporated in Delaware and has a fiscal year end on December 31. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Its Central Index Key (CIK) number is 0001787740, and the company has an Employer Identification Number (EIN) of 814016391.
Contact Details
The mailing and business address for Valion Bio, Inc. is 1305 E. Houston Street, Building 1, Suite 311, San Antonio, TX 78205. For inquiries, the company can be reached at (888) 276-6888.
"Accepted 2026-10-21 00:15:02" indicates the official acceptance time for the filing.
Document Availability
The filing includes various document formats, with the primary document available in both HTML and XML formats. The complete submission text file can also be accessed, providing further details on the filing.